Investing in Applied Genetic Technologies Corporation (AGTC)  ➔  Intrinsic value

Prev. close$3.43 
ModelValueUpside
Chepakovich$2.34-32%
Graham-Dodd$0.00-100%
Graham$32.10+836%
Previous Close$3.43  
Valuation MethodValuePotential 
Chepakovich Model$2.34-32%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$32.10+836%recalculate

Latest news

Company description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.